ES2175925T3 - Compuestos 4-(2-ceto-1-benzilimidazolinil)piperidina como agonistas del receptor orl1. - Google Patents
Compuestos 4-(2-ceto-1-benzilimidazolinil)piperidina como agonistas del receptor orl1.Info
- Publication number
- ES2175925T3 ES2175925T3 ES99900012T ES99900012T ES2175925T3 ES 2175925 T3 ES2175925 T3 ES 2175925T3 ES 99900012 T ES99900012 T ES 99900012T ES 99900012 T ES99900012 T ES 99900012T ES 2175925 T3 ES2175925 T3 ES 2175925T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- heterocyclic
- amino
- independently selected
- alkynyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
5 1. Un compuesto con la siguiente Fórmula: **fórmula** o las sales farmacéuticamente aceptables del mismo, en la que R 1 y R 2 son independientemente alquilo C1-C4; o R 1 y R 2 , junto con el átomo de carbono al que están unidos forman un grupo mono-, bi-, trio espirocíclico que tiene entre 6 y 13 átomos de carbono, en el que el grupo cíclico está opcionalmente sustituido con uno a cinco sustituyentes independientemente seleccionados entre alquilo C1-C4, alquileno C2-C4, alcoxi C1-C4, hidroxi, oxo, =CH2 y =CH-alquilo C1-C4; R 3 es alquilo C1-C7, alquenilo C2-C5, alquinilo C2-C5, fenil-alquilo-C1-C5, fenilo opcionalmente sustituido con uno a tres sustituyentes independientemente seleccionados entre úor, alquilo C1-C3 y alcoxi C1-C3, o un grupo heteroarilo seleccionado entre furilo, tienilo, pirrolilo y piridilo, en el que dicho grupo heteroarilo está opcionalmente sustituido con uno a tres sustituyentes independientemente seleccionados entre halógeno, alquilo C1-C3 y alcoxiC1-C3, con la condición de que cuando ambos R 1 y R 2 son alquilo C1-C4, entonces R 3 es distinto a alquilo C1-C7, alquenilo C2-C5 y alquinilo C2-C5; R 4 se selecciona entre: 1) hidrógeno, 2) alquilo (C1-C8), cicloalquilo (C3-C7), alquenilo (C2-C8), alquinilo (C2-C8), alquilo (C1-C6)-Z-, alquilo (C1-C6)-Z-alquilo (C1-C6), cicloalquilo (C3-C7)-Z-alquilo (C1-C6), alquenilo (C2-C6)-Z-alquilo (C1-C6) o alquinilo (C2-C6)-Z-alquilo (C1-C6), opcionalmente mono o disustituido donde Z se selecciona entre O, S, SO, SO2, CO,CO2, OCO, NR, CONR y NRCO, donde R es hidrógeno o alquilo (C1-C6) y los sustituyentes a unirse al radical alquilo, alquenilo, alquinilo o cicloalquilo se seleccionan independientemente entre halógeno, hidroxi, carboxi, amino, monoo di-(alquil C1-C4)amino, hidrazino, azido, ureido, amidino y guanidino; o 3) arilo, heterocíclico, arilalquilo (C1-C5), heterocíclico alquilo (C1-C5), heterocíclico-heterocíclico alquilo (C1-C5); arilheterocíclico alquilo (C1-C5); heterocíclico-Z-alquilo (C1-C5), aril-Z-alquilo (C1C5), arilalquilo (C1-C5)-Z-alquilo (C1-C5) oheterocíclico alquilo (C1-C5)-Z-alquilo (C1-C5), opcionalmente mono o disustituido, en el que el grupo arilo se selecciona entre fenilo, naftilo, indanilo, (1,2,3,4)-tetrahidronaftilo, indenilo e isoindenilo; el grupo heterocíclico se selecciona entre piperidino, hexametilenimino, morfolino, tiamorfolino, pirrolidino, pirazolino, pirazolidino, pirazorilo, piperazinilo, furilo, tienilo, oxazolilo, tetrazolilo, tiazolilo, imidazolilo, imidazolinilo, pirazolilo, piridilo, pirimidinilo, pirrolilo, pirrolidinilo, quinolilo, tiofenilo, pirazinilo, piridazinilo, aziridinilo y azetidinilo; en el que Z se selecciona entre O, S, SO, SO2, CO,CO2, OCO, NR, CONR y NRCO, en el que R es hidrógeno o alquilo (C1-C6) y los sustituyentes a los que se une el radical arilo o heterocíclico se seleccionan independientemente entre halógeno, hidroxi, carboxi, alquilo (C1-C4), halo alquilo (C1-C4), alcoxi (C1-C4), alquilo (C1-C4)-CO-, alquil (C1-C4) amino-CO-, fenilo, bencilo, amino, monoo di(alquil C1-C4)amino, hidrazino, azido, ureido, amidino y guanidino; R 5 se selecciona independientemente entre halógeno, alquilo C1-C3, alcoxi C1-C3, alquil(C1-C3) sulfonilo, CF3, carboxi, hidroxi, amino, alquilamino, acilamino, arilcarbonilo, alquilcarbonilo e hidroxialquilo y n es 0,1, 2, 3ó 4.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB9800069 | 1998-01-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2175925T3 true ES2175925T3 (es) | 2002-11-16 |
Family
ID=11004651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES99900012T Expired - Lifetime ES2175925T3 (es) | 1998-01-19 | 1999-01-08 | Compuestos 4-(2-ceto-1-benzilimidazolinil)piperidina como agonistas del receptor orl1. |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US6423725B1 (es) |
| EP (1) | EP1049689B1 (es) |
| JP (1) | JP3342478B2 (es) |
| CN (1) | CN1288464A (es) |
| AP (1) | AP9901442A0 (es) |
| AR (1) | AR014421A1 (es) |
| AT (1) | ATE219772T1 (es) |
| AU (1) | AU1679099A (es) |
| BG (1) | BG104670A (es) |
| BR (1) | BR9907104A (es) |
| CA (1) | CA2317462C (es) |
| CO (1) | CO4990962A1 (es) |
| DE (1) | DE69901934T2 (es) |
| DK (1) | DK1049689T3 (es) |
| EA (1) | EA200000683A1 (es) |
| ES (1) | ES2175925T3 (es) |
| GT (1) | GT199900008A (es) |
| IL (1) | IL137149A0 (es) |
| IS (1) | IS5539A (es) |
| MA (1) | MA26598A1 (es) |
| NO (1) | NO20003671L (es) |
| OA (1) | OA11445A (es) |
| PA (1) | PA8467101A1 (es) |
| PE (1) | PE20000166A1 (es) |
| PL (1) | PL342046A1 (es) |
| PT (1) | PT1049689E (es) |
| TN (1) | TNSN99006A1 (es) |
| TR (1) | TR200002090T2 (es) |
| WO (1) | WO1999036421A1 (es) |
| ZA (1) | ZA99314B (es) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6262066B1 (en) | 1998-07-27 | 2001-07-17 | Schering Corporation | High affinity ligands for nociceptin receptor ORL-1 |
| ATE289307T1 (de) * | 1998-10-23 | 2005-03-15 | Pfizer | 1,3,8-triazaspiro(4,5) decanon verbindungen als orl1-receptor agonisten |
| WO2000031061A1 (en) * | 1998-11-20 | 2000-06-02 | Banyu Pharmaceutical Co., Ltd. | 2-oxoimidazole derivatives |
| SE9903544D0 (sv) | 1999-10-01 | 1999-10-01 | Astra Pharma Prod | Novel compounds |
| ATE275141T1 (de) | 1999-10-13 | 2004-09-15 | Banyu Pharma Co Ltd | Substituierte imidazolin-derivate |
| US6686370B2 (en) | 1999-12-06 | 2004-02-03 | Euro-Celtique S.A. | Triazospiro compounds having nociceptin receptor affinity |
| EP1244437A4 (en) | 1999-12-06 | 2005-02-09 | Euro Celtique Sa | TERTIARY AMINO COMPOUNDS HAVING AFFINITY FOR OPIOID RECEPTOR |
| EP1242085B1 (en) * | 1999-12-06 | 2005-08-24 | Euro-Celtique, S.A. | Benzimidazole compounds having nociceptin receptor affinity |
| GB2359078A (en) | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| GB2359081A (en) | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active thiazolopyrimidines |
| GB2359551A (en) | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| GB0005642D0 (en) | 2000-03-10 | 2000-05-03 | Astrazeneca Uk Ltd | Chemical compounds |
| SE0003828D0 (sv) | 2000-10-20 | 2000-10-20 | Astrazeneca Ab | Novel compounds |
| WO2002040019A1 (en) * | 2000-11-15 | 2002-05-23 | Banyu Pharmaceutical Co.,Ltd. | Benzimidazole derivatives |
| SE0101322D0 (sv) | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | Novel compounds |
| NZ551453A (en) * | 2001-04-18 | 2008-02-29 | Euro Celtique Sa | Nociceptin analogs for the treatment of pain |
| US6872733B2 (en) * | 2001-04-18 | 2005-03-29 | Euro-Celtique S.A. | Benzimidazolone compounds |
| KR100628292B1 (ko) | 2001-04-18 | 2006-09-27 | 유로-셀티크 소시에떼 아노뉨 | 스파이로파이라졸 화합물 |
| KR100855204B1 (ko) | 2001-04-18 | 2008-09-01 | 유로-셀티크 소시에떼 아노뉨 | 노시셉틴 유사체 |
| PT1385514E (pt) | 2001-04-18 | 2009-02-04 | Euro Celtique Sa | Compostos espiroindeno e espiroindano |
| DE10123163A1 (de) * | 2001-05-09 | 2003-01-16 | Gruenenthal Gmbh | Substituierte Cyclohexan-1,4-diaminderivate |
| JP3896309B2 (ja) | 2001-07-09 | 2007-03-22 | ファイザー株式会社 | プロテインキナーゼｃ阻害物質としてのピラゾロキノリノン誘導体 |
| JP4056977B2 (ja) * | 2002-03-29 | 2008-03-05 | 田辺三菱製薬株式会社 | 睡眠障害治療薬 |
| JP2005289816A (ja) * | 2002-05-14 | 2005-10-20 | Banyu Pharmaceut Co Ltd | ベンズイミダゾール誘導体 |
| GB0221828D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
| EP1560807B1 (de) | 2002-11-12 | 2010-02-10 | Grünenthal GmbH | 4-hydroxymethyl-1-aryl-cyclohexylamin-derivative |
| SA04250305B1 (ar) * | 2003-09-25 | 2008-06-02 | سولفاي فارماسوتيكالز بي . في | مشتقات بنزيميدازولون cenzimidazolone وكينازولينون quinazolinone كمساعادات على مستقبلات ORL1 البشرية |
| AR045843A1 (es) * | 2003-10-03 | 2005-11-16 | Solvay Pharm Bv | Derivados de bencimidazolonas y quinazolinonas sustituidas con hidronopol como agonistas en receptores orl 1 humanos |
| GB0328243D0 (en) | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Methods |
| AR054816A1 (es) * | 2005-07-13 | 2007-07-18 | Banyu Pharma Co Ltd | Derivados de n-dihidroxialquil 2-oxo- imidazol sustituidos |
| US7300947B2 (en) * | 2005-07-13 | 2007-11-27 | Banyu Pharmaceutical Co., Ltd. | N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives |
| EP1954137A4 (en) * | 2005-11-18 | 2008-12-17 | Janssen Pharmaceutica Nv | 2-KETO-OXAZOLE AS MODULATORS OF FATTY ACID AMIDHYDROLASE |
| JP2009525269A (ja) | 2006-01-30 | 2009-07-09 | ユーロ−セルティーク エス．エイ． | カルシウムチャネルブロッカーとしての環状尿素化合物 |
| GB0605786D0 (en) * | 2006-03-22 | 2006-05-03 | Glaxo Group Ltd | Compounds |
| GB0605784D0 (en) * | 2006-03-22 | 2006-05-03 | Glaxo Group Ltd | Compounds |
| CN101600433B (zh) * | 2006-10-16 | 2012-09-26 | 田边三菱制药株式会社 | 用于预防或治疗酒精依赖或药物依赖的药剂 |
| EP2280008B1 (en) * | 2007-01-16 | 2013-05-29 | Purdue Pharma L.P. | Heterocyclic-substituted piperidines as orl-1 ligands |
| EP2128154B1 (en) * | 2007-03-01 | 2015-04-08 | Mitsubishi Tanabe Pharma Corporation | Benzimidazole compound and pharmaceutical use thereof |
| TW201322983A (zh) * | 2007-08-31 | 2013-06-16 | Purdue Pharma Lp | 經取代之喹□啉型哌啶化合物及其用途 |
| US8119661B2 (en) | 2007-09-11 | 2012-02-21 | Astrazeneca Ab | Piperidine derivatives and their use as muscarinic receptor modulators |
| TW201016675A (en) | 2008-09-16 | 2010-05-01 | Mitsubishi Tanabe Pharma Corp | Crystalline benzoimidazole compound and salt thereof |
| WO2011157793A1 (en) * | 2010-06-17 | 2011-12-22 | Novartis Ag | Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
| WO2014153529A1 (en) | 2013-03-22 | 2014-09-25 | The Scripps Research Institute | Substituted benzimidazoles as nociceptin receptor modulators |
| RU2019120099A (ru) * | 2016-11-28 | 2020-12-30 | Мицубиси Танабе Фарма Корпорейшн | Лекарственное средство для лечения кокаиновой наркозависимости или предотвращения ее рецидива |
| CA3087886A1 (en) | 2018-01-19 | 2019-07-25 | Idorsia Pharmaceuticals Ltd | C5a receptor modulators |
| CN116496270B (zh) * | 2022-01-27 | 2024-09-24 | 四川大学华西医院 | 一类4-氨基哌啶衍生物及其制备方法和用途 |
| WO2025146193A1 (zh) * | 2024-01-05 | 2025-07-10 | 宜昌人福药业有限责任公司 | 一种环己基取代哌啶衍生物、包含其的药物组合物及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3161645A (en) | 1962-12-18 | 1964-12-15 | Res Lab Dr C Janssen N V | 1-(1-aroylpropyl-4-piperidyl)-2-benzimidazolinones and related compounds |
| US3318900A (en) * | 1964-05-06 | 1967-05-09 | Janssen Pharmaceutica Nv | Derivatives of benzimidazolinyl piperidine |
| JPS58180481A (ja) | 1982-04-15 | 1983-10-21 | Kyowa Hakko Kogyo Co Ltd | 新規なピペリジン誘導体 |
| AT388731B (de) * | 1987-12-15 | 1989-08-25 | Gerot Pharmazeutika | Neue derivate von benzimidazol, ihre herstellung und verwendung |
| WO1997016186A1 (en) * | 1995-10-31 | 1997-05-09 | Merck & Co., Inc. | Muscarine agonists |
| ZA9610745B (en) * | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
| WO1997040035A1 (en) | 1996-04-19 | 1997-10-30 | Neurosearch A/S | 1-(4-piperidyl)-benzimidazoles having neurotrophic activity |
| WO1998054168A1 (en) | 1997-05-30 | 1998-12-03 | Banyu Pharmaceutical Co., Ltd. | 2-oxoimidazole derivatives |
-
1999
- 1999-01-08 EA EA200000683A patent/EA200000683A1/ru unknown
- 1999-01-08 EP EP99900012A patent/EP1049689B1/en not_active Expired - Lifetime
- 1999-01-08 CA CA002317462A patent/CA2317462C/en not_active Expired - Fee Related
- 1999-01-08 PL PL99342046A patent/PL342046A1/xx not_active Application Discontinuation
- 1999-01-08 PT PT99900012T patent/PT1049689E/pt unknown
- 1999-01-08 WO PCT/IB1999/000012 patent/WO1999036421A1/en not_active Ceased
- 1999-01-08 AT AT99900012T patent/ATE219772T1/de not_active IP Right Cessation
- 1999-01-08 ES ES99900012T patent/ES2175925T3/es not_active Expired - Lifetime
- 1999-01-08 CN CN99802227A patent/CN1288464A/zh active Pending
- 1999-01-08 DK DK99900012T patent/DK1049689T3/da active
- 1999-01-08 DE DE69901934T patent/DE69901934T2/de not_active Expired - Fee Related
- 1999-01-08 AU AU16790/99A patent/AU1679099A/en not_active Abandoned
- 1999-01-08 JP JP2000540137A patent/JP3342478B2/ja not_active Expired - Fee Related
- 1999-01-08 US US09/403,408 patent/US6423725B1/en not_active Expired - Fee Related
- 1999-01-08 BR BR9907104-5A patent/BR9907104A/pt not_active Application Discontinuation
- 1999-01-08 TR TR2000/02090T patent/TR200002090T2/xx unknown
- 1999-01-08 IL IL13714999A patent/IL137149A0/xx unknown
- 1999-01-14 AP APAP/P/1999/001442A patent/AP9901442A0/en unknown
- 1999-01-15 TN TNTNSN99006A patent/TNSN99006A1/fr unknown
- 1999-01-15 PA PA19998467101A patent/PA8467101A1/es unknown
- 1999-01-15 MA MA25432A patent/MA26598A1/fr unknown
- 1999-01-18 AR ARP990100184A patent/AR014421A1/es unknown
- 1999-01-18 ZA ZA9900314A patent/ZA99314B/xx unknown
- 1999-01-18 PE PE1999000041A patent/PE20000166A1/es not_active Application Discontinuation
- 1999-01-19 CO CO99002592A patent/CO4990962A1/es unknown
- 1999-01-19 GT GT199900008A patent/GT199900008A/es unknown
-
2000
- 2000-06-16 IS IS5539A patent/IS5539A/is unknown
- 2000-07-07 OA OA1200000203A patent/OA11445A/en unknown
- 2000-07-18 NO NO20003671A patent/NO20003671L/no not_active Application Discontinuation
- 2000-08-07 BG BG104670A patent/BG104670A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1049689B1 (en) | 2002-06-26 |
| AR014421A1 (es) | 2001-02-28 |
| US6423725B1 (en) | 2002-07-23 |
| DK1049689T3 (da) | 2002-07-22 |
| EA200000683A1 (ru) | 2000-12-25 |
| GT199900008A (es) | 2000-07-12 |
| IL137149A0 (en) | 2001-07-24 |
| BR9907104A (pt) | 2000-10-24 |
| MA26598A1 (fr) | 2004-12-20 |
| DE69901934D1 (de) | 2002-08-01 |
| ZA99314B (en) | 2000-07-18 |
| WO1999036421A1 (en) | 1999-07-22 |
| PA8467101A1 (es) | 2000-09-29 |
| CO4990962A1 (es) | 2000-12-26 |
| NO20003671L (no) | 2000-09-18 |
| PL342046A1 (en) | 2001-05-21 |
| AU1679099A (en) | 1999-08-02 |
| ATE219772T1 (de) | 2002-07-15 |
| IS5539A (is) | 2000-06-16 |
| PT1049689E (pt) | 2002-09-30 |
| EP1049689A1 (en) | 2000-11-08 |
| PE20000166A1 (es) | 2000-03-07 |
| BG104670A (en) | 2001-05-31 |
| JP2002509148A (ja) | 2002-03-26 |
| NO20003671D0 (no) | 2000-07-18 |
| TNSN99006A1 (fr) | 2005-11-10 |
| DE69901934T2 (de) | 2002-11-07 |
| AP9901442A0 (en) | 1999-03-31 |
| CN1288464A (zh) | 2001-03-21 |
| CA2317462A1 (en) | 1999-07-22 |
| TR200002090T2 (tr) | 2000-11-21 |
| CA2317462C (en) | 2005-09-13 |
| OA11445A (en) | 2004-04-30 |
| JP3342478B2 (ja) | 2002-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2175925T3 (es) | Compuestos 4-(2-ceto-1-benzilimidazolinil)piperidina como agonistas del receptor orl1. | |
| AR066669A1 (es) | Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas. | |
| CO5631432A2 (es) | Derivados de n-[fenil(piepidin-2-il)metil]benzamida, su preparacion y su aplicacion en terapeutica | |
| NO20044866L (no) | Pyrazolo-pyrimidin-anilin-forbindelser anvendelige som kinase-inhibitorer | |
| AR055051A1 (es) | Compuestos de tiazol y oxazol y composiciones farmaceuticas que los contienen. | |
| CO5550421A2 (es) | Derivados de indol utiles para el tratamiento de enfermeda- des | |
| AR038703A1 (es) | Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3 | |
| PE20020585A1 (es) | Inhibidores de metaloproteinasa del tipo pirimidin-2,4,6-triona | |
| AR118724A1 (es) | Inhibidores de dihidroorotato deshidrogenasa | |
| AR045587A1 (es) | Derivados de acil piperazinas sustituidas, proceso de obtencion, uso y composiciones farmaceuticas que las contienen | |
| CO5540299A2 (es) | Derivados de tiazol u oxazol que son utiles en el tratamiento de enfermedades cardiovasculares y relacionadas | |
| CO6170361A2 (es) | Composiciones y metodos para modular receptores de c-kit y pdgfr | |
| MX2007003433A (es) | Sintesis de n-fluorobencil) -n- (1-metilpiperidin-4-il) -n'- (4- (2-metilpropiloxi) fenilmetil) carbamida y su sal de tartrato y formas cristalinas. | |
| CO5670367A2 (es) | Derivados de acido fenoxiacetico | |
| ECSP088479A (es) | Derivados de oxadiazol | |
| CR8468A (es) | Derivado de n-(1,5-difenil-1h-pirazol-3-il)metil)sulfonamida con afinidad por los receptores cb1 | |
| HN2005000030A (es) | Derivados de sulfonamida para el tratamiento de enfermedades | |
| PY08034070A (es) | Derivados de 1, 2, 4, 5-tetrahidro -3-H- benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen. | |
| CO5611152A2 (es) | Compuestos derivados piperidina caracterizados por ser antagonistas del receptor de las taquicininas, especialmente del receptor nk1 y composiciones farmaceuticas que los contienen | |
| RU2012143212A (ru) | Способ лечения артрита | |
| AR044821A1 (es) | 4-(aminometil)-piperidin benzamidas como antagonistas de 5ht4 | |
| CO4920224A1 (es) | Compuestos de pirrolidinil y pirrolinil etilamina como agonistas kappa | |
| NO20074346L (no) | Nye heterocykliske oksimforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem | |
| CO5590858A2 (es) | Composicion fungicida basada en un derivado de piridilmetilbenzamida e iprovalicarb | |
| ES2249636T3 (es) | Triazoles como antagonistas de la oxitocina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 1049689 Country of ref document: ES |